The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

PRESENTATION
Vibrance-2: A Randomized Phase 2 Study Evaluating Efficacy and Safety of the Orexin 2 Receptor Agonist Alixorexton in Patients With Narcolepsy Type 2
Author(s):

Richard K. Bogan,1 Giuseppe Plazzi,2,3 Emmanuel Mignot,4 Rafael del Río Villegas,5,6 Bruce Corser,7 Brendon J. Yee,8 Diego García-Borreguero,9 Chad Ruoff,10 David T. Plante,11 Hailu Chen,12 Alexandra Lovett,12 Michael J. Doane,12 Craig Hopkinson,12 Bhaskar Rege,12 Julie Himes12

1University of South Carolina School of Medicine, Columbia, SC, USA; 2IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy; 3University of Modena and Reggio-Emilia, Modena, Italy; 4Stanford Center for Sleep Sciences and Medicine, Stanford University School of Medicine, Stanford, CA, USA; 5Neurophysiology and Sleep Disorders Unit, Vithas Madrid Hospitals, Madrid, Spain; 6Departamento de Ciencias Médicas Clínicas, Universidad CEU San Pablo, CEU Universities, Madrid, Spain; 7Intrepid Research, Cincinnati, OH, USA; 8Woolcock Institute of Medical Research, Macquarie University, Sydney, Australia; 9Sleep Research Institute, Madrid, Spain; 10Mayo Clinic, Scottsdale, AZ, USA; 11University of Wisconsin-Madison, School of Medicine and Public Health, Madison, WI, USA; 12Alkermes, Inc., Waltham, MA, USA
 

Content available until 06/14/2029